Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Smith & Nephew plc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.05, while Smith & Nephew plc trades at $30.11 (market cap $12.73B). The key difference: Smith & Nephew plc pays a 2.57% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| AIQ | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $38.70 |
52-Week Low | $43.28 | $28.73 |
Market Cap | — | $12.73B |
Enterprise Value | — | $15.50B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Smith & Nephew (SNN) trades at $30.48, up 0.76% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $5.8B in 2024 to $6.2B in 2025 and net income margin expanding to 10.13%. Recent product launches in robotics and wound care demonstrate innovation momentum. Technical indicators show support at $30 and resistance at $31, with moving averages signaling bullish momentum.
SNN presents a mixed investment case with strong revenue growth and margin expansion offset by inconsistent earnings performance. The company's $500M share buyback and positive 2026 outlook provide support, but recent earnings misses and cautious analyst sentiment (68% hold rating) suggest near-term caution. Key risks include execution challenges and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
